fasitibant
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT01091116)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Bradykinin B2 receptorANTAGONIST
BDKRB2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(C)c2cccc(OCc3c(Cl)ccc(S(=O)(=O)NC4(C(=O)N5CCN(C(=O)[C@@H](N)CCC[N+](C)(C)C)CC5)CCOCC4)c3Cl)c2n1- Mol. weight
- 764.8 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL218427 ↗
- ChEMBLCHEMBL541758 ↗
Also known as
- (4-amino-5-(4-(4-(2,4-dichloro-3-(2,4-dimethyl-8-quinolyloxymethyl)phenylsulfonamido)tetrahydro-2h-4-pyranoylcarbonyl)piperazino)-5-oxopentyl)(trimethyl)ammonium
- fasitibant
- fasitibant
- fasitibant
- fasitibant
- fasitibant chloride
- fasitibant chloride
- men16132
- men16132
- men16132
- men 16132
- men-16132
- men-16132
- men-16132
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02205814 | Phase 2 | Apr 1, 2014 | Charles University, Menarini Group |
| NCT01091116 | Phase 2 | Mar 1, 2010 | Charles University, Menarini Group |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Charles University | Academic/Hospital | 2 | 0 | 1 | 2010 |
| Menarini Group | For profit | 2 | 2 | 1 | 2010 |
2 organizations
Page 1 / 1